Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of daprodustat versus darbepoetin alfa for renal anemia in maintenance hemodialysis patients with chronic kidney disease
CTR20254383Phase 3Active
- Sponsor
- Bocimed Pharmaceutical
- Start
- Aug 2026
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in anemia of chronic kidney disease comparing Daprodustat with Darbepoetin alfa (2 arms). Primary endpoint: Mean change in hemoglobin from baseline. Started Aug 2026; status: active.
02
Drugs
daprodustatdarbepoetin alfa
03
Conditions
anemia of chronic kidney disease
Beyond the preview
Go deeper on CTR20254383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254383.